RedHill Biopharma Ltd.
RedHill Biopharma Ltd. (RDHL) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
rdhl · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for RedHill Biopharma Ltd. (RDHL) measures how much investors pay for each dollar of the company's trailing earnings. RDHL's current PE ratio of N/A is calculated by dividing its stock price of $0.88 by its TTM earnings per share of -$3.73.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2010 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
RedHill Biopharma Ltd.You RDHL | $3M | N/A | — | -$3.73 |
 Akanda Corp. AKAN | $0M | N/A | — | -$245.68 |
 Bio Green Med Solution, Inc. BGMS | $2M | N/A | — | -$1.37 |
 BNB Plus Corp. BNBX | $1M | N/A | — | -$29.29 |
 CNS Pharmaceuticals, Inc. CNSP | $3M | N/A | — | -$35.75 |
 Flora Growth Corp. FLGC | $4M | N/A | — | $0.00 |
 GlucoTrack, Inc. GCTK | $0M | N/A | — | -$21.56 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.14 | — | |
2024-12-31 FY2024 | — | $-3.35 | — | |
2023-12-31 FY2023 | 0.79x | $46.15 | — | |
2022-12-31 FY2022 | — | $-578.64 | — | |
2021-12-31 FY2021 | — | $-1050.40 | — | |
2020-12-31 FY2020 | — | $-1045.56 | — | |
2019-12-31 FY2019 | — | $-712.38 | — | |
2018-12-31 FY2018 | — | $-839.53 | — | |
2017-12-31 FY2017 | — | $-1289.69 | — | |
2016-12-31 FY2016 | — | $-1142.71 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for RedHill Biopharma Ltd. (RDHL) measures how much investors pay for each dollar of the company's trailing earnings. RDHL's current PE ratio of N/A is calculated by dividing its stock price of $0.88 by its TTM earnings per share of -$3.73.
Frequently asked questions
RDHL pe ratio · 6 questionsRDHL's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.88 and TTM EPS of -$3.73. Data sourced from Financial Modeling Prep via RDHL's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · RedHill Biopharma Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09